• Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Money Profit News
No Result
View All Result
Home Breaking News

CDC steps up its Covid vaccine booster recommendation amid concerns about omicron variant

by
November 30, 2021
in Breaking News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Related Posts

Top U.S., Chinese and Russian officials tour Africa as diplomatic charm offensive gathers pace

Tesla, Nvidia Lead Today’s Biggest S&P 500 Stock Market Losers

Amazon, Qualcomm Partner Driving Breakout With 778% Growth

China’s January factory activity returns to growth as economists cheer its reopening

Rochelle Walensky, director of the U.S. Centers for Disease Control and Prevention (CDC), speaks during a Senate Health, Education, Labor, and Pensions Committee hearing in Washington, D.C., on Thursday, Nov. 4, 2021.

Al Drago | Bloomberg | Getty Images

The Centers for Disease Control and Prevention on Monday strengthened its recommendation on Covid booster shots, telling all adults that they “should” get an additional dose amid growing concern about the newly identified omicron variant.

“The recent emergence of the Omicron variant (B.1.1.529) further emphasizes the importance of vaccination, boosters, and prevention efforts needed to protect against COVID-19,” CDC Director Dr. Rochelle Walensky said in a statement Monday.

The CDC cleared booster doses for all adults earlier this month, saying everyone over 18 “may” get a shot if they wanted one. Only people 50 and over were told they “should” get the shots at the time. The agency is now giving its strongest recommendation for everyone 18 and older, saying they should get an additional shot six months after their initial Pfizer or Moderna series, or two months after their first Johnson & Johnson shot.

The World Health Organization, in a paper published Sunday, warned that global risk posed by omicron is “very high.” The variant has more than 30 mutations on its spike protein alone, some of which are associated with higher transmission and reduced antibody protection. The WHO said these mutations could fuel future surges of infection with “severe consequences.”

“Early data from South Africa suggest increased transmissibility of the Omicron variant, and scientists in the United States and around the world are urgently examining vaccine effectiveness related to this variant,” Walensky said.

Though omicron is believed to be more infectious than the predominant delta variant, it is not yet clear how much the heavily mutated strain will affect the strength of currently available vaccines. Moderna and Pfizer said they will have more data on this in about two weeks. The companies maintain that they can adjust their vaccines relatively quickly to combat new variants.

“I don’t think that the result will be the vaccines don’t protect,” Pfizer CEO Albert Bourla told CNBC’s “Squawk Box” on Monday. “I think the result could be, which we don’t know yet, the vaccines protect less.”

Bourla said that Pfizer can develop a new vaccine within 100 days. Moderna CEO Stephane Bancel told CNBC on Monday that the company could deploy a higher-dosage booster shot against omicron quickly but a variant-specific vaccine could take months.

Though omicron has not yet been detected in the U.S., President Joe Biden on Monday said the country will face the variant sooner or later, and encouraged Americans to get booster shots for added protection. Walensky, in her Monday statement, urged people to get tested as well.

“I also want to encourage people to get a COVID-19 test if they are sick,” Walensky said. “Increased testing will help us identify Omicron quickly.”

The emergence of omicron comes as public health officials are already concerned about a winter Covid surge and declining vaccine strength.

A study published in the journal Science this month found that the Pfizer vaccine’s efficacy at preventing infection declined from 86% to 43% from February to October. Moderna’s vaccine dropped from 89% to 58%, and J&J’s vaccine fell from 86% to 13% efficacy against infection in the same study.

However, Pfizer found that its booster dose provides 95% protection against symptomatic infection in a clinical trial of 10,000 people.

Next Post

Tuesday: Case-Shiller House Prices, FHFA Conforming Loan Limits, Fed Chair Powell Testimony and More

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Breaking News

Top U.S., Chinese and Russian officials tour Africa as diplomatic charm offensive gathers pace

by
January 31, 2023
0

Janet Yellen, US Treasury secretary, during a news conference with Enoch Godongwana, South Africa's finance minister, at the National Treasury...

Read more

Top U.S., Chinese and Russian officials tour Africa as diplomatic charm offensive gathers pace

Tesla, Nvidia Lead Today’s Biggest S&P 500 Stock Market Losers

Amazon, Qualcomm Partner Driving Breakout With 778% Growth

UniCredit shares rise as bank hikes payout goal by 40% after record profit

China’s January factory activity returns to growth as economists cheer its reopening

Dow Jones Falls 260 Points Ahead Of Fed Meeting, Big Earnings; What To Do Now

Load More

All rights reserved by www.moneyprofitnews.com

  • Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

moneyprofitnews